Literature DB >> 6947218

Kallikrein-induced uterine contraction independent of kinin formation.

J Chao, J Buse, K Shimamoto, H S Margolius.   

Abstract

Responses of smooth muscle to kallikreins (EC 3.4.21.8) are generally considered to result from kinin formation. This premise was reexamined with the isolated rat uterus. Rat urinary kallikrein or bradykinin produced dose-dependent contractions of rat uterus but kallikrein was 5-fold more potent than bradykinin. Kallikrein caused an immediate series of rhythmic contractions which could be increased gradually with subsequent addition of kininogen substrate. Kallikrein-induced contractions were unaffected by carboxypeptidase B or a bradykinin antiserum whereas bradykinin-induced contractions were attenuated or abolished. Other serine proteinases, including trypsin, either did not induce contraction in the absence of added kininogen or did so minimally. Although small amounts of kininogen-like substrate were found in uterine tissue, detectable kinin levels (greater than 4 pg) could not be found in bathing media during maximal kallikrein-induced contractions or after uterine tissue was incubated with high concentrations of the enzyme in the presence of SQ 20881, a kininase II inhibitor. The data suggest that uterine contraction produced by a homologous kallikrein does not involve kinin formation but results from an action of this serine proteinase upon other accessible systems coupled to the contractile response.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6947218      PMCID: PMC348996          DOI: 10.1073/pnas.78.10.6154

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  18 in total

1.  A micromethod for determination of bradykininogen under several conditions.

Authors:  C R DINIZ; I F CARVALHO
Journal:  Ann N Y Acad Sci       Date:  1963-02-04       Impact factor: 5.691

2.  Isozymes of rat urinary kallikrein.

Authors:  J Chao; H S Margolius
Journal:  Biochem Pharmacol       Date:  1979-07-01       Impact factor: 5.858

3.  Proteolytic enzyme activation of rat ovarian adenylate cyclase.

Authors:  N D Richert; R J Ryan
Journal:  Proc Natl Acad Sci U S A       Date:  1977-11       Impact factor: 11.205

4.  A method for measurement of urinary kallikrein.

Authors:  M Marin-Grez; O A Carretero
Journal:  J Appl Physiol       Date:  1972-03       Impact factor: 3.531

5.  Human urinary kallikrein converts inactive to active renin and is a possible physiological activator of renin.

Authors:  J E Sealey; S A Atlas; J H Laragh; N B Oza; J W Ryan
Journal:  Nature       Date:  1978-09-14       Impact factor: 49.962

6.  Purification of rat urinary kallikreins and their specific antibody.

Authors:  K Nustad; J V Pierce
Journal:  Biochemistry       Date:  1974-05-21       Impact factor: 3.162

7.  Oxytocic esterase in rat urine.

Authors:  W T Beraldo; R L Araujo; M Mares-Guia
Journal:  Am J Physiol       Date:  1966-10

8.  Identification of human glandular kallikrein in the beta cell of the pancreas.

Authors:  O K ole-MoiYoi; G S Pinkus; J Spragg; K F Austen
Journal:  N Engl J Med       Date:  1979-06-07       Impact factor: 91.245

9.  The effect of aprotinin on luteolytic and uterine contractile mechanisms in the pregnant rat at term.

Authors:  E T Whalley; A J Riley
Journal:  J Reprod Fertil       Date:  1979-03

10.  A sensitive radioimmunoassay method for urinary kinins in man.

Authors:  K Shimamoto; T Ando; T Nakao; S Tanaka; M Sakuma; M Miyahara
Journal:  J Lab Clin Med       Date:  1978-05
View more
  10 in total

Review 1.  Molecular biology of tissue kallikrein.

Authors:  R J MacDonald; H S Margolius; E G Erdös
Journal:  Biochem J       Date:  1988-07-15       Impact factor: 3.857

2.  Kallikrein activates bradykinin B2 receptors in absence of kininogen.

Authors:  Dauren Biyashev; Fulong Tan; Zhenlong Chen; Kai Zhang; Peter A Deddish; Ervin G Erdös; Claudie Hecquet
Journal:  Am J Physiol Heart Circ Physiol       Date:  2005-11-04       Impact factor: 4.733

3.  Mechanism of trypsin-induced contraction in the rat myometrium: the possible involvement of a novel member of protease-activated receptor.

Authors:  Y Shintani; K Hirano; T Nakayama; J Nishimura; H Nakano; H Kanaide
Journal:  Br J Pharmacol       Date:  2001-08       Impact factor: 8.739

4.  Guinea pig plasma kallikrein as a vascular permeability enhancement factor. Its dependence on kinin generation and regulation mechanisms in vivo.

Authors:  T Imamura; T Yamamoto; T Kambara
Journal:  Am J Pathol       Date:  1984-04       Impact factor: 4.307

5.  The myostimulating effect of tissue kallikrein on rat uterus.

Authors:  J Damas; V Bourdon; J C Pinto
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-05       Impact factor: 3.000

6.  Tissue kallikrein elicits cardioprotection by direct kinin b2 receptor activation independent of kinin formation.

Authors:  Julie Chao; Hang Yin; Lin Gao; Makoto Hagiwara; Bo Shen; Zhi-Rong Yang; Lee Chao
Journal:  Hypertension       Date:  2008-09-02       Impact factor: 10.190

7.  A novel signaling pathway of tissue kallikrein in promoting keratinocyte migration: activation of proteinase-activated receptor 1 and epidermal growth factor receptor.

Authors:  Lin Gao; Lee Chao; Julie Chao
Journal:  Exp Cell Res       Date:  2009-10-30       Impact factor: 3.905

8.  Tissue kallikrein synthesis and its modification by testosterone or low dietary sodium.

Authors:  D H Miller; J Chao; H S Margolius
Journal:  Biochem J       Date:  1984-02-15       Impact factor: 3.857

Review 9.  Evidence for activation of Toll-like receptor and receptor for advanced glycation end products in preterm birth.

Authors:  Taketoshi Noguchi; Toshiyuki Sado; Katsuhiko Naruse; Hiroshi Shigetomi; Akira Onogi; Shoji Haruta; Ryuji Kawaguchi; Akira Nagai; Yasuhito Tanase; Shozo Yoshida; Takashi Kitanaka; Hidekazu Oi; Hiroshi Kobayashi
Journal:  Mediators Inflamm       Date:  2010-11-28       Impact factor: 4.711

Review 10.  Human tissue kallikrein in the treatment of acute ischemic stroke.

Authors:  Michelle Alexander-Curtis; Rick Pauls; Julie Chao; John J Volpi; Philip M Bath; Todd A Verdoorn
Journal:  Ther Adv Neurol Disord       Date:  2019-01-20       Impact factor: 6.570

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.